Cellular Logistics
Cellular Logistics is a pioneering biotech company based in Madison, Wisconsin, focused on developing regenerative medicine technologies for cardiac therapy. Their flagship product, CFX™, is an innovative biomaterial designed to treat and prevent heart failure following myocardial infarction and in chronic heart failure cases. The company aims to revolutionize heart disease treatment through its advanced stem cell and biomaterial technologies, seeking collaborations and investments to scale and commercialize its solutions.
Industries
Nr. of Employees
small (1-50)
Cellular Logistics
Products
Injectable biomaterial for acute post-myocardial infarction intervention
A tunable particulate, cell-free biomaterial formulated for local injection soon after myocardial infarction to reduce pathological remodeling and the progression to heart failure.
Biomaterial patch for chronic heart failure support with cell co-therapy
A thin, pliable epicardial patch designed to be applied to the heart surface to support remuscularization when used in combination with therapeutic stem cells.
Injectable biomaterial for acute post-myocardial infarction intervention
A tunable particulate, cell-free biomaterial formulated for local injection soon after myocardial infarction to reduce pathological remodeling and the progression to heart failure.
Biomaterial patch for chronic heart failure support with cell co-therapy
A thin, pliable epicardial patch designed to be applied to the heart surface to support remuscularization when used in combination with therapeutic stem cells.
Services
Commercial licensing and strategic collaborations to integrate the biomaterial platform into partner product development programs.
Process refinement and scale-up consulting to transition reproducible laboratory production methods to cGMP manufacturing.
Design and execution support for preclinical studies focused on immune response, angiogenesis, and functional cardiac outcomes to de-risk clinical translation.
Commercial licensing and strategic collaborations to integrate the biomaterial platform into partner product development programs.
Process refinement and scale-up consulting to transition reproducible laboratory production methods to cGMP manufacturing.
Design and execution support for preclinical studies focused on immune response, angiogenesis, and functional cardiac outcomes to de-risk clinical translation.
Expertise Areas
- Cardiac regenerative therapies
- Biomaterial formulation and delivery
- Induced pluripotent stem cell-derived product development
- Cell therapy delivery and retention enhancement
Key Technologies
- Induced pluripotent stem cell-derived biomaterials
- Injectable particulate biomaterials
- Thin pliable epicardial patch formats
- Cell-binding matrix technologies
News & Updates
Interested in learning more about the Catalyze program? Join us on March 19 at 12pm ET for a live webinar where a panel of four funded investigators will describe their Catalyze project and summarize key takeaways from the program. Time will be reserved for audience questions. March...
UW Center for Technology Commercialization
UW–Madison’s Discovery to Product (D2P)
Interested in learning more about the Catalyze program? Join us on March 19 at 12pm ET for a live webinar where a panel of four funded investigators will describe their Catalyze project and summarize key takeaways from the program. Time will be reserved for audience questions. March...
UW Center for Technology Commercialization
UW–Madison’s Discovery to Product (D2P)